Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
Eligible age
All ages
Accepts
All genders
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.
Sponsor: University of Pennsylvania
You may qualify if…
- ✓ Patients with a diagnosis of eosinophilic granulomatosis with polyangiitis are eligible for the study.
- ✓ Parent or guardian willing to provide informed consent, if applicable
You may not qualify if…
- ✕ \- Inability to give informed consent and to sign the consent form
Where it's recruiting
San Diego
Denver
Boston
Rochester
Cleveland
Philadelphia · Pittsburgh
Salt Lake City
Source: ClinicalTrials.gov · NCT00315380 · last updated 2026-08-28